Immunosuppressive treatment ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症3

66. IgA腎症


臨床試験数 : 255 薬物数 : 255 - (DrugBank : 79) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 137
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03468972
(ClinicalTrials.gov)
March 201912/3/2018Effect of Immunosuppression in IgA NephropathyEffect of Immunosuppression in IgA NephropathyBiopsy-proven IgA NephropathyDrug: Immunosuppressive treatment;Other: intensive supportive careYonsei UniversityNULLNot yet recruiting19 Years75 YearsAll174Phase 4Korea, Republic of
2NCT03015974
(ClinicalTrials.gov)
January 20163/1/2017Registry of IgA Nephropathy in Chinese ChildrenRegistry of IgA Nephropathy in Chinese ChildrenIgA Nephropathy;Proteinuria in Nephrotic Range;Immunosuppressive TreatmentDrug: Corticosteroid;Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Dipyridamole;Drug: ACE Inhibitor or Angiotensin receptor antagonistPeking University First HospitalNanjing PLA General Hospital;Beijing Children's Hospital;Central South University;The Children's Hospital of Zhejiang University School of Medicine;First Affiliated Hospital, Sun Yat-Sen University;Tongji Hospital;Hunan Children's Hospital;Shanghai Children's Hospital;Nanjing Children's Hospital;Children's Hospital of Chongqing Medical University;Shandong Provincial Hospital;Fuzhou General Hospital;Second Affiliated Hospital of Wenzhou Medical University;Children's Hospital of Hebei Province;Guangzhou Women and Children's Medical Center;Jiangxi Province Children's Hospital;Guangzhou First People's Hospital;Xian Children's Hospital;Capital Institute of Pediatrics, China;First Hospital of Jilin University;Wuhan Women and Children's Medical Center;Tianjin Children's Hospital;Chengdu Women's and Children's Central Hospital;The First People's Hospital of YunnanRecruiting1 Month18 YearsAll1200China
3NCT02523768
(ClinicalTrials.gov)
January 8, 20114/8/2015Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentPrevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentGlomerulonephritis;IgANDrug: ATG-F;Drug: SimulectCentre Hospitalier Universitaire de Saint EtienneNULLTerminated18 Years75 YearsAll117Phase 4France